Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.50-$9.50 vs $9.13 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $281.535M Est

Benzinga Newsdesk www.benzinga.com Negative 49.7%

Neg 49.7% Neu 0% Pos 0%

Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.50-$9.50 to $8.50-$9.50 vs $9.13 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000 million-$310.000 million vs $281.535 million estimate.